(P140) Clinical Predictors of Survival for Patients With Stage IV Cancer Referred to Radiation Oncology

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

These data suggest that a model that considers performance status, extent of disease, serum albumin, mental status, and primary tumor site represents a clinically relevant tool in radiation oncology to predict survival for patients with stage IV cancer.

Emily Copel, DO, Johnny Kao, MD, Kenneth Gold, MD, Gina Zarilli, MD, Samuel Ryu, MD, David Yens, PhD; Good Samaritan Medical Center; State University of New York, Stony Brook; New York College of Osteopathic Medicine

PURPOSE: To develop a clinically useful predictive model for survival in a heterogeneous group of patients with metastatic cancer referred to radiation oncology.

PATIENTS AND METHODS: From May 2012 to August 2013, a total of 143 consecutive patients with stage IV cancer were prospectively evaluated by a single radiation oncologist. We retrospectively analyzed the effects of 29 patient-, laboratory-, and tumor-related prognostic factors on overall survival (OS), using univariate analysis. Variables that were statistically significant on univariate analysis were entered into a multivariable Cox regression model to identify independent predictors of long-term survival.

RESULTS: The median OS was 5.6 months. Five prognostic factors significantly predicted survival on multivariable analysis: Eastern Cooperative Oncology Group (ECOG) performance status (0/1 vs 2 vs 3/4), number of active tumors (1–5 vs ≥ 6), albumin levels (≥ 3.4 mg/dL vs 2.4–3.3 mg/dL vs < 2.4 mg/dL), altered mental status (no vs yes), and primary tumor site (breast, kidney, or prostate vs other). Risk group stratification was performed by assigning points for adverse prognostic factors, resulting in favorable-, standard-, and poor-risk groups. The median survival was 21.8 months for favorable risk vs 5.5 months for standard risk and 1.5 months for poor risk (P < .001).

CONCLUSIONS: These data suggest that a model that considers performance status, extent of disease, serum albumin, mental status, and primary tumor site represents a clinically relevant tool in radiation oncology to predict survival for patients with stage IV cancer.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content